EPA/DHA对非对比T1加权成像检测的冠状动脉高信号斑块的影响(AQUAMARINE EPA/DHA研究):随机对照试验的研究方案
本研究为前瞻性、随机、开放标签、对照试验,旨在评估他汀治疗的冠心病患者接受12个月EPA/DHA治疗对心脏磁共振非对比T1加权成像检测的高信号斑块(以斑块-心肌信号强度比PMR量化)的影响。受试者随机分为2 g/天EPA/DHA组、4 g/天EPA/DHA组和无治疗组,主要终点为EPA/DHA治疗后PMR的变化。
要点
- 他汀治疗的冠心病患者仍存在心血管事件残余风险,LC n-3 PUFAs(EPA/DHA)是潜在抗动脉粥样硬化药物。
- 非对比T1加权心脏磁共振可无创识别高危冠状动脉斑块为高信号,并以PMR定量评估。
- 本试验比较2 g/天、4 g/天EPA/DHA与无治疗组,主要终点为12个月后PMR变化。
核心结论
- 本试验将评估EPA/DHA是否通过PMR对高危冠状动脉斑块产生抗动脉粥样硬化效应,并可能为降低他汀治疗冠心病患者的残余风险提供新策略。
研究设计与样本
- 前瞻性、对照、随机、开放标签研究,在冠心病患者中比较12个月EPA/DHA治疗联合他汀与单用他汀对CMR检测的HIPs的PMR及CTA指标的影响。
- 受试者随机分配至2 g/天EPA/DHA组、4 g/天EPA/DHA组或无治疗组。
- 主要终点为EPA/DHA治疗后PMR的变化;次要终点包括CTA测量的Hounsfield单位、斑块体积、血管面积和斑块面积的变化。
关键数值与推荐
- 主要终点:EPA/DHA治疗后PMR的变化。
- 次要终点:CTA测量的Hounsfield单位、斑块体积、血管面积和斑块面积的变化。
- 干预分组:2 g/天EPA/DHA组、4 g/天EPA/DHA组、无治疗组。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the success of HMG-CoA reductase inhibitor (statin) therapy in reducing atherosclerotic cardiovascular events, a residual risk for cardiovascular events in patients with coronary artery disease (CAD) remains. Long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs), especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are promising anti-atherosclerosis agents that might reduce the residual CAD risk. Non-contrast T1-weighted imaging (T1WI) with cardiac magnetic resonance (CMR) less invasively identifies high-risk coronary plaques as high-intensity signals. These high-intensity plaques (HIPs) are quantitatively assessed using the plaque-to-myocardium signal intensity ratio (PMR). Our goal is to assess the effect of EPA/DHA on coronary HIPs detected with T1WI in patients with CAD on statin treatment. METHODS/DESIGN: This prospective, controlled, randomized, open-label study examines the effect of 12 months of EPA/DHA therapy and statin treatment on PMR of HIPs detected with CMR and computed tomography angiography (CTA) in patients with CAD. The primary endpoint is the change in PMR after EPA/DHA treatment. Secondary endpoints include changes in Hounsfield units, plaque volume, vessel area, and plaque area measured using CTA. Subjects are randomly assigned to either of three groups: the 2 g/day EPA/DHA group, the 4 g/day EPA/DHA group, or the no-treatment group. DISCUSSION: This trial will help assess whether EPA/DHA has an anti-atherosclerotic effect using PMR of HIPs detected by CMR. The trial outcomes will provide novel insights into the effect of EPA/DHA on high-risk coronary plaques and may provide new strategies for lowering the residual risk in patients with CAD on statin therapy. TRIAL REGISTRATION: The University Hospital Medical Information Network (UMIN) Clinical Trials Registry, ID: UMIN000015316 . Registered on 2 October 2014.
引用
- Nakao K, Noguchi T, Asaumi Y, et al. Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial. Trials. 2018. PMID: 29310688. doi:10.1186/s13063-017-2353-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。